title: Dramatic Response to Catumaxomab Treatment for Malign Ascites Related to Renal Cell Carcinoma With Sarcomotoid Differentiation.
abstract: Refractory malignant ascites (MA) is a common complication in cancer patients. Renal cell carcinoma (RCC) is rarely present with peritoneal ascites, which is commonly associated with carcinomas of the gastrointestinal and female reproductive tracts; including especially ovarian high-grade serous carcinoma. Currently, chemotherapy and paracentesis represent the most widely used methods to relieve the symptoms. Recently, intraperitoneal therapy with catumaxomab-a trifunctional hybrid antibody-has been introduced for the treatment of MA. The benefit of this treatment has been demonstrated in patients with distinct abdominal malignancies. In this case report, we present the first case of successful catumaxomab treatment against MA in a patient with advanced RCC with sarcomatoid differentiation. After the second administration of catumaxomab, paracentesis became no longer necessary. Catumaxomab might represent a safe treatment option for MA in the course of metastatic RCC with sarcomatoid differentiation.
authors.affiliation: Departments of 1Medical Oncology, 2Urology, 3Radiology, and 4Pathology, Faculty of Medicine, Bilim University; and 5Department of Radiology, Gayrettepe Florence Nightingale Hospital, Instanbul, Turkey.
authors.forename: Kezban Nur
authors.initials: KN
authors.lastname: Pilanc
authors.forename: Çetin
authors.initials: Ç
authors.lastname: Ordu
authors.forename: Haluk
authors.initials: H
authors.lastname: Akpnar
authors.forename: Cem
authors.initials: C
authors.lastname: Balc
authors.forename: Nuray
authors.initials: N
authors.lastname: Başsülü
authors.forename: Ülkühan İner
authors.initials: Üİ
authors.lastname: Köksal
authors.forename: Filiz
authors.initials: F
authors.lastname: Elbüken
authors.forename: Kerem
authors.initials: K
authors.lastname: Okutur
authors.forename: Gülen
authors.initials: G
authors.lastname: Bülbül
authors.forename: Sezer
authors.initials: S
authors.lastname: Sağlam
authors.forename: Gökhan
authors.initials: G
authors.lastname: Demir
mesh_terms: D018033:Antibodies, Bispecific / Q000008:administration & dosage / Q000627:therapeutic use*; D001201:Ascites / Q000188:drug therapy* / Q000209:etiology*; D002292:Carcinoma, Renal Cell / Q000150:complications*; D006801:Humans; D007274:Injections, Intraperitoneal; D008875:Middle Aged; D009367:Neoplasm Staging
chemical_list: D018033:Antibodies, Bispecific; C522419:catumaxomab